# KALA BIO, INC. (KALA) · Edgar & Edgarette company card

> Kala Bio (KALA) reported revenue of $0 million in FY2025, operating margin null against a -3.8% median for pharmaceutical preparations, equity 73.7% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1479419 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/KALA) · [JSON](https://www.pops4.com/boards/company/KALA.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -Infinity%) |
| Net margin | -Infinity% |
| Operating cash flow | −$32M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $8M |
| Long-term debt | — |
| Total assets | $9M |
| Total equity | $7M |
| Equity ÷ assets | 73.7% |
| Return on equity | -385.6% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -258.66 (distress zone)
- Piotroski F: 1 of 9 (weak)
- Health Harbor boat: Old boat · three warning signs · filed late annual report notice, late quarterly report notice, auditor change in the last 12 months; operating cash flow was negative (-$32.0M in FY2025); operating loss: a margin of -Infinity% in FY2025

## Edgarette's reading

Exposure: revenue $0K (FY2025). Experience: one year on record; operating margin null, up from null. Soundness: equity 73.7% of assets, return on equity -385.6%. Credibility: four or more audited years, reasonable weight. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-03-31 ([filing](https://www.sec.gov/Archives/edgar/data/1479419/000182912626002931/0001829126-26-002931-index.htm))
- Item 3.01 Exchange listing notice or transfer: 3, latest 2026-08-28 ([filing](https://www.sec.gov/Archives/edgar/data/1479419/000182912626009454/0001829126-26-009454-index.htm))
- Item NT 10-Q Late quarterly report notice: 2, latest 2026-08-14 ([filing](https://www.sec.gov/Archives/edgar/data/1479419/000182912626008832/0001829126-26-008832-index.htm))
- Item 4.01 Auditor change: 2, latest 2025-12-29 ([filing](https://www.sec.gov/Archives/edgar/data/1479419/000182912625010330/0001829126-25-010330-index.htm))
- Item 5.02 Director or officer change: 5, latest 2026-02-20 ([filing](https://www.sec.gov/Archives/edgar/data/1479419/000182912626001534/0001829126-26-001534-index.htm))

## Recent filings

- 8-K · filed 2026-11-03 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1479419/000182912626011934/0001829126-26-011934-index.htm)
- DEF 14A · filed 2026-09-24 · [filing](https://www.sec.gov/Archives/edgar/data/1479419/000182912626010384/0001829126-26-010384-index.htm)
- 8-K · filed 2026-09-10 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1479419/000182912626009999/0001829126-26-009999-index.htm)
- 8-K · filed 2026-09-09 · 5.08 Shareholder Nominations Pursuant to Rule 14a-11; 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1479419/000182912626009946/0001829126-26-009946-index.htm)
- 8-K · filed 2026-08-28 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule · [filing](https://www.sec.gov/Archives/edgar/data/1479419/000182912626009454/0001829126-26-009454-index.htm)
- 10-Q · filed 2026-08-19 · [filing](https://www.sec.gov/Archives/edgar/data/1479419/000110465926098783/0001104659-26-098783-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001479419.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1479419

## Cite

POPS4, Edgar & Edgarette: KALA BIO, INC. (KALA) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/KALA. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.